Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1497-1504

  Zhao, Yanan ^a   Stensvold, Christen R ^b   Perlin, David S ^a   Arendrup, Maiken C ^b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

A. fumigatus; Azole resistant; CYP51A PCR; GM

Indexed keywords

AMINO ACID; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FUNGUS CULTURE; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TANDEM REPEAT;

EID: 84879479980     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt071     Document Type: Article

References (40)

1. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
2. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp. report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44: 1782-7.
3. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-8.
4. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007- 2009. Emerg Infect Dis 2011; 17: 1846-54.
5. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
6. Horvath JA, Dummer S. The use of respiratory-33333tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171-8.
7. Einsele H, Quabeck K, Muller KD, et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998; 352: 1443.
8. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24: 1195-9.
9. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45: 2462-72.
10. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasiv pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 1043-50.
11. Arendrup MC, Bille J, Dannaoui E, et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012; 47: 1030-45.
12. Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 2010; 54: 2425-30.
13. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother 2011; 55: 2483-6.
14. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 Suppl 1: S90-5.
15. Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56: 10-6.
16. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-9.
17. Mortensen KL, Mellado E, Lass-Florl C, et al. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010; 54: 4545-9.
18. Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49: 2243-51.
19. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50: 1258-63.
20. de Hoog GS, Guarro J, Gene J,, et al. Atlas of Clinical Fungi. Washington, DC: ASM Press, 2000.
21. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2468-72.
22. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
23. Zhao Y, Park S, Warn P, et al. Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol 2010; 48: 1378-83.
24. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008; 46: 1200-6.
25. Van der Linden J, Arendrup M, Verweij P, et al. Prospective international surveillance of azole resistance (AR) in Aspergillus fumigatus (Af) (SCARE-Network). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract M-490. American Society for Microbiology, Washington, DC, USA.
26. Denning DW, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 Suppl 3: S265-80.
27. Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52: 1218-6.
28. Walsh TJ, Wissel MC, Grantham KJ, et al. Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis. J Clin Microbiol 2011; 49: 4150-7.
29. Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49: 4273-8.
30. Aquino VR, Nagel F, Andreolla HF, et al. The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD). Mycopathologia 2012; 174: 163-9.
31. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48: 1231-40.
32. Harrison E, Stalhberger T, Whelan R, et al. Aspergillus DNA contamination in blood collection tubes. Diagn Microbiol Infect Dis 2010; 67: 392-4.
33. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, et al. Identification of two different 14-a sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001; 39: 2431-8.
34. Herrera ML, Vallor AC, Gelfond JA, et al. Strain-dependent variation in 18S ribosomal DNA copy numbers in Aspergillus fumigatus. J Clin Microbiol 2009; 47: 1325-32.
35. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward?. Curr Opin Infect Dis 2009; 22: 568-73.
36. Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 2010; 5: e10080.
37. Mavridou E, Bruggemann RJ, Melchers WJ, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates withmutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54: 860-5.
38. Alanio A, Cabaret O, Sitterle E, et al. Azole preexposure affects the Aspergillus fumigatus population in patients. Antimicrob Agents Chemother 2012; 56: 4948-50.
39. Escribano P, Recio S, Pelaez T, et al. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother 2011; 55: 2460-2.
40. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. Substitutions at methionine 220 in the 14a-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48: 2747-50.